TrialDrugs in R&D2025

Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg.

Yasmin Sánchez-Pearson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.